. Author manuscript; available in PMC: 2009 Jul 30.

Published in final edited form as: Alzheimer Dis Assoc Disord. 2008;22(3):209–221. doi: 10.1097/WAD.0b013e31816653bc

Table 3.

Effect size estimates for ADL favor COMBO treatment over NO-RX and over CI alone. Also displayed for each group are the predicted mean ADL scores and 95% confidence intervals at one-year intervals.

	ADL, model predicted mean %-dependent (95% confidence interval)			Cohen’s d_ADL

Years in Study	NO-RX	CI	COMBO	CI vs NO-RX	COMBO vs NO-RX	COMBO vs CI
1	36.9 (34.6–39.2)	35.7 (32.9–38.5)	32.4 (29.7–35.1)	0.08	0.32^*	0.23
2	49.7 (46.9–52.6)	49.5 (46.0–53.0)	41.2 (37.8–44.6)	0.02	0.48^***	0.46^***
3	62.0 (58.5–65.4)	62.6 (58.5–66.7)	49.4 (45.3–53.4)	−0.03	0.60^***	0.62^***
4	73.6 (69.5–77.6)	75.0 (70.2–80.0)	56.9 (52.1–61.7)	−0.06	0.67^***	0.73^***

significantly different from zero; p < 0.05

^**

p < 0.01

^***

p < 0.001